- Home
- GIGM vs SIGA Comparison
GIGM vs SIGA Comparison
Compare GIGM & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | SIGA |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 223.8M |
| IPO Year | 2002 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GIGM | SIGA |
|---|---|---|
| Price | $1.37 | $2.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.2K | ★ 671.6K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | ★ N/A | $23.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $2.83 |
| 52 Week High | $1.86 | $9.45 |
Technical Indicators
Market Signals| Indicator | GIGM | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 50.34 |
| Support Level | $1.32 | $2.87 |
| Resistance Level | $1.53 | $3.32 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 57.22 | 58.54 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.